View presentations from the experts from the 3rd Annual Young Investigators Forum in Lung Cancer focusing on leadership skills, presentation skills, updates on the management of EGFRm and ALK-positive lung cancers, immunotherapy for stage III and stage IV disease, and new technology being used in the management of lung cancer.
4.75 AMA PRA Category 1 Credits™
Apr 27, 2018
Apr 27, 2019
Keynote presentation: Leadership skills
Gary L. Teal
Lecia V. Sequist, MD, MPH
Shirish Gadgeel, MD
Immunotherapy for stage IV disease
Natasha Leighl, BSc, MSc, MD
Immunotherapy for stage III disease
Nasser Hanna, MD
New technology in the management of lung cancer: Which is best used for what?
David Carbone, MD, PhD
Julie Brahmer, MD, and Suresh Ramalingam, MD
Julie Brahmer, MDSidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland, United States
David Carbone, MD, PhDComprehensive Cancer Center
Ohio State University
Columbus, Ohio, United States
Judy FortinWinship Cancer Institute
Atlanta, Georgia, United States
Shirish Gadgeel, MDUniversity of Michigan
Ann Arbor, Michigan, United States
Nasser Hanna, MDMelvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
Natasha Leighl, BSc, MSc, MDPrincess Margaret Hospital
Toronto, Ontario, Canada
Suresh Ramalingam, MDWinship Cancer Institute
Atlanta, Georgia, United States
Lecia V. Sequist, MDMassachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts, United States
Gary L. Teal, MBAWoodruff Health Sciences Center
Atlanta, Georgia, United States
This educational activity is specifically designed to meet the needs of medical oncologists and other healthcare professionals involved in the treatment of patients with lung cancer.
After successful completion of this educational activity, participants should be able to:
- Assess clinical trial design, endpoints, and rationale
- Select treatment based upon disease and patient characteristics
- Evaluate recent data from national society meetings that have the potential to impact practice, including immunotherapy, targeted therapies, sequencing, and combination therapy
Endorsed by Emory Winship Cancer Institute.
This educational activity is supported by a grant from AstraZeneca.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
prIME Oncology designates this enduring material for a maximum of 4.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is provided by prIME Oncology.
Method of Participation
Links to the posttest are available on the video player pages.
In order to receive credit, participants must successfully complete the online posttest with 75% or higher.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Brahmer has disclosed that she has received consulting fees from Celgene, Lilly, and Merck. She also disclosed independent contracting for Bristol-Myers Squibb, Merck, and MedImmune/AstraZeneca. She is also a member on an advisory committee or review panel for Merck. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Carbone has disclosed that he has served as a consultant or advisory board member for Abbvie; Adaptimmune; Agenus; Amgen; Ariad; AstraZeneca; Biocept; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; EMD Serono, Inc; Foundation Medicine; Genentech/Roche; Gritstone; Guardant Health; Inovio; Merck; MSD; Novartis; Palobiofarma; Pfizer; Stemcentrx; and Takeda. He also received a research grant from Bristol-Myers Squibb. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Judy Fortin has disclosed that she has no relevant financial relationships to report. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Gadgeel has disclosed that he has received consulting fees from Abbvie, Ariad, AstraZeneca, Roche, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Hanna has disclosed independent contracting for Bristol-Myers Squibb and Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Leighl has disclosed that she has received honoraria for speaking and teaching from Bristol-Myers Squibb and MSD. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Ramalingam has disclosed that he has received consulting fees from Abbvie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Genentech, Lilly, Merck, and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Sequist has disclosed that she has received consulting fees from AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Genentech, Merrimack, Novartis, and Pfizer. She also disclosed independent contracting for AstraZeneca, Boehringer-Ingelheim, Genentech, Merrimack, Merck, Novartis, Johnson & Johnson, and Pfizer. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Gary Teal has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.